[MPI] QoQ Cumulative Quarter Result on 30-Jun-2023 [#4]

Stock
[MPI] MALAYSIAN PACIFIC INDUSTRIES
Announcement Date
28-Aug-2023
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2023
Quarter
30-Jun-2023 [#4]
Profit Trend
QoQ- 15.3%
YoY- -81.35%
Quarter Report
Latest QR
Upcoming QR
MPI's Result
MPI's Financial Summary
View:
Show?
Cumulative Result
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Revenue 1,562,016 1,035,961 513,210 2,044,721 1,562,295 1,090,434 564,015 97.08%
PBT 137,252 85,376 35,122 124,328 107,678 111,067 73,795 51.18%
Tax -12,931 -7,825 -5,088 -16,180 -16,633 -11,585 -6,135 64.31%
NP 124,321 77,551 30,034 108,148 91,045 99,482 67,660 49.96%
-
NP to SH 81,425 48,670 16,519 61,334 53,197 71,029 52,699 33.61%
-
Tax Rate 9.42% 9.17% 14.49% 13.01% 15.45% 10.43% 8.31% -
Total Cost 1,437,695 958,410 483,176 1,936,573 1,471,250 990,952 496,355 103.06%
-
Net Worth 2,120,391 2,070,340 2,042,497 2,014,654 2,048,330 2,042,086 2,056,005 2.07%
Dividend
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Div 69,618 19,888 19,888 69,608 69,603 19,884 19,884 130.39%
Div Payout % 85.50% 40.86% 120.39% 113.49% 130.84% 27.99% 37.73% -
Equity
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Net Worth 2,120,391 2,070,340 2,042,497 2,014,654 2,048,330 2,042,086 2,056,005 2.07%
NOSH 209,884 209,884 209,884 209,884 209,884 209,884 209,884 0.00%
Ratio Analysis
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
NP Margin 7.96% 7.49% 5.85% 5.29% 5.83% 9.12% 12.00% -
ROE 3.84% 2.35% 0.81% 3.04% 2.60% 3.48% 2.56% -
Per Share
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
RPS 785.28 520.90 258.05 1,028.12 785.60 548.40 283.65 97.04%
EPS 40.94 24.47 8.31 30.84 26.75 35.72 26.50 33.60%
DPS 35.00 10.00 10.00 35.00 35.00 10.00 10.00 130.34%
NAPS 10.66 10.41 10.27 10.13 10.30 10.27 10.34 2.05%
Adjusted Per Share Value based on latest NOSH - 209,884
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
RPS 783.94 519.92 257.57 1,026.20 784.08 547.26 283.07 97.08%
EPS 40.87 24.43 8.29 30.78 26.70 35.65 26.45 33.61%
DPS 34.94 9.98 9.98 34.93 34.93 9.98 9.98 130.39%
NAPS 10.6417 10.3905 10.2508 10.1111 10.2801 10.2487 10.3186 2.07%
Price Multiplier on Financial Quarter End Date
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Date 29/03/24 29/12/23 29/09/23 30/06/23 31/03/23 30/12/22 30/09/22 -
Price 31.00 28.20 27.46 27.82 28.96 28.76 28.74 -
P/RPS 3.95 5.41 10.64 2.71 3.69 5.24 10.13 -46.59%
P/EPS 75.73 115.23 330.60 90.21 108.26 80.51 108.44 -21.26%
EY 1.32 0.87 0.30 1.11 0.92 1.24 0.92 27.18%
DY 1.13 0.35 0.36 1.26 1.21 0.35 0.35 118.28%
P/NAPS 2.91 2.71 2.67 2.75 2.81 2.80 2.78 3.09%
Price Multiplier on Announcement Date
31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 30/09/22 CAGR
Date 16/05/24 21/02/24 15/11/23 28/08/23 18/05/23 16/02/23 23/11/22 -
Price 33.50 26.18 27.18 26.30 27.80 33.74 27.60 -
P/RPS 4.27 5.03 10.53 2.56 3.54 6.15 9.73 -42.22%
P/EPS 81.84 106.98 327.23 85.28 103.93 94.45 104.14 -14.82%
EY 1.22 0.93 0.31 1.17 0.96 1.06 0.96 17.30%
DY 1.04 0.38 0.37 1.33 1.26 0.30 0.36 102.70%
P/NAPS 3.14 2.51 2.65 2.60 2.70 3.29 2.67 11.40%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment